Chemotherapy and Surgery vs Chemoradiation for Cervical Cancer: No Survival Difference, Higher Short-Term Toxicity

Chemotherapy followed by radical surgery shows little to no difference in five-year survival rates compared to standard chemoradiotherapy for locally advanced cervical cancer, according to a Cochrane systematic review. However, the surgical approach likely increases short-term severe unwanted effects while offering highly uncertain evidence regarding disease recurrence.

Cervical cancer originates in the lower part of the womb and is almost universally driven by persistent infection with the human papillomavirus (HPV). When tumours grow large or invade neighbouring pelvic tissues without spreading to distant organs, clinicians diagnose locally advanced cervical cancer. In resource-limited regions lacking organised screening programmes and widespread HPV vaccination, this disease remains a frequent cause of cancer mortality.

For decades, standard medical consensus has favoured combining chemotherapy medicines with radiation, known as chemoradiotherapy. Yet, access to radiotherapy machines varies widely globally, and radiation frequently triggers severe unwanted effects. Medical researchers have long investigated whether administering chemotherapy first to shrink the tumour, followed by surgical removal, might serve as a viable alternative.

  • Survival Parity: Five-year survival rates show little to no measurable difference between initial chemotherapy with surgery versus standard chemoradiotherapy.
  • Toxicity Risks: Patients who undergo chemotherapy followed by surgery face a higher probability of severe short-term unwanted effects.
  • Standard of Care: Chemoradiotherapy remains the established treatment choice wherever high-quality radiation facilities are accessible to patients.

Three Trials with 1,326 Women Compared Treatments

To determine the comparative safety and efficacy of these approaches, investigators searched electronic databases including CENTRAL, MEDLINE, Embase, and ClinicalTrials.gov up to May 20, 2026, as reported in the Cochrane Database of Systematic Reviews by Antonios Athanasiou, Sarah J Bowden, Evangelos Paraskevaidis et al.

Their analysis evaluated three randomised controlled trials encompassing a total of 1,326 women. Two of these clinical trials took place in India, while the third trial spanned 25 medical centres across 10 European countries.

When examining overall survival across two studies involving 1,259 women, researchers found little to no difference in how long patients lived after five years. However, data regarding cancer recurrence and progression remained highly uncertain.

Evidence from a single study of 635 women showed that disease progression might be higher following the surgical pathway, though confidence in this finding remains low. Short-term serious adverse events occurred more often in the surgical cohort, as documented across two studies involving 1,224 women.

Clinical Endpoint Participant Count Study Count Comparative Finding
Overall Survival (5-Year) 1,259 women 2 studies Little to no difference between treatment groups
Cancer Progression Risk 626 women 1 study Possible higher chance of worsening, but evidence is very uncertain
Short-Term Serious Adverse Events 1,224 women 2 studies Probably greater number of events in the surgery group

Additional context from a separate systematic review published in the National Library of Medicine (PMC7403931) noted specific haematological and gastrointestinal differences. That analysis reported that the incidence of thrombocytopenia—a dangerous drop in platelet count—was significantly higher in the neoadjuvant chemotherapy and radical surgery group, with a relative risk of 3.240. Conversely, the incidence of diarrhoea was significantly lower compared to patients receiving radiation-based regimens.

Authors of the Cochrane review expressed only moderate to very low confidence in the overarching evidence base. A major methodological hurdle involved cross-over treatment rates, as a large number of women initially assigned to chemotherapy and surgery ultimately required subsequent radiotherapy. This overlapping intervention makes isolating the independent therapeutic effect of each individual modality exceptionally difficult for clinical researchers.

Long-term toxicological assessments also suffered from historical inconsistencies. The radiotherapy techniques utilised in the older trials fail to reflect modern, precision-guided radiation oncology practices currently deployed in high-resource healthcare systems. Consequently, researchers concluded that current evidence does not support neoadjuvant chemotherapy followed by radical surgery as a standard alternative to chemoradiotherapy.

Insufficient Evidence for Chemotherapy-Surgery Substitute

Where high-quality radiotherapy infrastructure is unavailable, medical authorities emphasise that current clinical trial evidence remains insufficient to routinely recommend chemotherapy followed by surgery as a safe, equivalent substitute. More rigorous, high-quality clinical studies with modern radiation protocols are urgently required to tailor therapeutic decisions to individual patient profiles.

References

  • Athanasiou A, Bowden SJ, Paraskevaidis E, et al. Neoadjuvant chemotherapy and surgery versus chemoradiotherapy for locally advanced cervical cancer. Cochrane Database of Systematic Reviews. 2026. DOI: 10.1002/14651858.cd014684
  • PMC National Center for Biotechnology Information. Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Patients with Cervical Cancer. PMC7403931
  • World Health Organization. Guidelines for Cervical Cancer Control. WHO Reproductive Health Publications
Photo of author

Health Desk

Health Desk at Archyde.

GTA VI Mods Enable 60 FPS via Neural Rendering on PC Streaming

Highlights of a Jaunt to the Bay of Naples: Myth, Geology, and History